Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ABBVIE INC.

(ABBV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Communiqués de presse de la société ABBVIE INC.
10/12ABBVIE : Allergan Aesthetics Launches Series of Initiatives to Support Breast Cancer Aware..
AQ
10/08ABBVIE : Upadacitinib (RINVOQ) Met Primary and Most Ranked Secondary Endpoints in Phase 3 ..
AQ
10/08ABBVIE : RINVOQ (upadacitinib) Met Primary and All Ranked Secondary Endpoints in Phase 3 S..
AQ
10/07ABBVIE : Health Canada Approves the Use of RINVOQ® (upadacitinib) for the Treatment of Adu..
AQ
10/07ABBVIE : 's Upadacitinib (RINVOQ®) Met Primary and Most Ranked Secondary Endpoints in Phas..
PR
10/07ABBVIE : 's RINVOQ® (upadacitinib) Met Primary and All Ranked Secondary Endpoints in Phase..
PR
10/05ABBVIE : to Host Third-Quarter 2021 Earnings Conference Call
PR
10/02ABBVIE : to Showcase New Data at the United European Gastroenterology (UEG) Week Virtual 2..
PR
10/01ABBVIE : Presents New Analyses Evaluating RINVOQ (upadacitinib) in Atopic Dermatitis Acros..
AQ
09/30ABBVIE : Presents New Analyses Evaluating RINVOQ® (upadacitinib) in Atopic Dermatitis Acro..
PR
09/29ABBVIE : FDA Approves QULIPTA (atogepant), the First and Only Oral CGRP Receptor Antagonis..
AQ
09/28ABBVIE : FDA Approves QULIPTA™ (atogepant), the First and Only Oral CGRP Receptor An..
PR
09/23ABBVIE : Presents New Data Analyses for Growing Dermatology Portfolio at the 30th European..
PR
09/22ABBVIE : N.D. Ill. Finds That A Foreign Parent Corp. May Be Sued Under BPCIA Without The U..
AQ
09/20ABBVIE : Submits Regulatory Application to FDA for Risankizumab-rzaa (SKYRIZI®) for the Tr..
PR
09/16ABBVIE : Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) for the..
PR
09/14ABBVIE : and REGENXBIO Announce Eye Care Collaboration
AQ
09/13ABBVIE : Declares Quarterly Dividend
AQ
09/13ABBVIE : to Highlight Its Leadership in Movement Disorders at the International Parkinson ..
AQ
09/10ABBVIE : Declares Quarterly Dividend
PR
09/10ABBVIE : Clinical Trial of Investigational Epcoritamab (DuoBody-CD3xCD20) in Patients with..
AQ
09/10ABBVIE : to Highlight Its Leadership in Movement Disorders at the International Parkinson ..
PR
09/09ABBVIE : to Present at the Morgan Stanley Healthcare Conference
PR
09/08ABBVIE : to Present Data From Its Migraine Portfolio at the 2021 International Headache Co..
PR
09/01ABBVIE : named to PEOPLE's “Companies that Care” list for third consecutive ye..
PU
08/26ABBVIE : Receives a Positive Reimbursement Recommendation from the Canadian Agencies for D..
AQ
08/24ABBVIE : European Commission Approves RINVOQ® (upadacitinib) as First JAK Inhibitor in the..
PR
08/19ABBVIE : Aims to Support Patients with Myelofibrosis, a Rare Blood Cancer
PU
08/19ABBVIE INC. : Other Events (form 8-K)
AQ
08/19ABBVIE : New England Journal of Medicine Publishes 12-Week Results from Study Evaluating A..
AQ
08/19SANUWAVE INC. ASSETS GET ANOTHER VAL : Snwv)
AQ
08/12ABBVIE : Ventures Launches Inaugural AIM Award
PU
08/10ABBVIE : SKYRIZI (risankizumab-rzaa) Now Available in the U.S. as a Single 150 mg Injectio..
AQ
08/09TAKEDA PHARMACEUTICAL : Updates its Q1 FY2021 Earnings Materials to Reflect Impact of Deci..
AQ
08/09ABBVIE : SKYRIZI® (risankizumab-rzaa) Now Available in the U.S. as a Single 150 mg Injecti..
PR
08/04ABBVIE : JAMA Dermatology Publishes Data Showing RINVOQ® (upadacitinib) Achieved Superiori..
PR
08/02ABBVIE : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERAT..
AQ
08/02ABBVIE : Reports Second-Quarter 2021 Financial Results
AQ
07/30ABBVIE : Allergan - FDA Approves Expanded BOTOX Label to Include Eight New Muscles to Trea..
AQ
07/30ABBVIE : Reports Second-Quarter 2021 Financial Results (Form 8-K)
PU
07/30ABBVIE : Reports Second-Quarter 2021 Financial Results
PU
07/30ABBVIE : Q2 Earnings Snapshot
AQ
07/30ABBVIE INC. : Results of Operations and Financial Condition, Financial Statements and Exhi..
AQ
07/29ABBVIE : FDA Approves Expanded BOTOX® (onabotulinumtoxinA) Label to Include Eight New Musc..
PR
07/27ABBVIE : and Calico Announce Second Extension of Collaboration Focused on Aging and Age-Re..
PR
07/26ABBVIE : New Data Presented on the Safety and Efficacy of Investigational AGN-190584 as a ..
AQ
07/23ABBVIE : DALVANCE® (dalbavancin) Receives FDA Approval to Treat Acute Bacterial Skin and S..
PR
07/22ABBVIE : Venetoclax (VENCLEXTA) Granted US FDA Breakthrough Therapy Designation (BTD) in H..
AQ
07/21ABBVIE : Allergan, an AbbVie Company, to Present New Data from its Leading Eye Care Portfo..
AQ
07/19ABBVIE : Provides Update Regarding RINVOQ (upadacitinib) for the Treatment of Moderate to ..
AQ
07/16ABBVIE : Provides Update Regarding RINVOQ® (upadacitinib) for the Treatment of Moderate to..
PR
07/08Collaboration Between AbbVie, Biogen and Pfizer Creates World’s Largest Browsable..
AQ
07/07ABBVIE : to Host Second-Quarter 2021 Earnings Conference Call
PR
06/30ABBVIE : Upadacitinib (RINVOQ) Met the Primary and All Secondary Endpoints in the 52-Week ..
AQ
06/29ABBVIE : Upadacitinib (RINVOQ®) Met the Primary and All Secondary Endpoints in the 52-Week..
PR
06/28ABBVIE : Gastroenterology Pipeline to be Featured at the 16th Congress of European Crohn's..
PR
06/25ABBVIE : Provides Update Regarding RINVOQ® (upadacitinib) in Psoriatic Arthritis and Ankyl..
PR
06/25ABBVIE : CHMP Recommends Approval of RINVOQ® (upadacitinib) for the Treatment of Atopic De..
PR
06/24ABBVIE : Exercises Right to Acquire TeneoOne and Lead Asset TNB-383B for the Potential Tre..
PR
06/17ABBVIE : Declares Quarterly Dividend
PR
06/15ABBVIE : SANUWAVE's Valuation Could Surge After AbbVie Starts A Bidding War In The Shockwa..
AQ
06/14ABBVIE : New Data Shows AbbVie's VENCLYXTO/VENCLEXTA Fixed Duration Combination Demonstrat..
AQ
06/14ABBVIE : IMBRUVICA Plus VENCLEXTA VENCLYXTO Combination Shows Superior Progression-Free Su..
AQ
06/11ABBVIE : New Data Shows AbbVie's VENCLYXTO®/VENCLEXTA® Fixed Duration Combination Demonstr..
PR
06/09ABBVIE : Allergan Aesthetics and BOTOX Cosmetic (onabotulinumtoxinA) Put Real Stories at t..
AQ
06/08ABBVIE : CAPTIVATE Study Shows an IMBRUVICA (ibrutinib) Plus VENCLEXTA/VENCLYXTO (venetocl..
AQ
06/08ABBVIE : Allergan Aesthetics and BOTOX® Cosmetic (onabotulinumtoxinA) Put Real Stories at ..
PR
06/07ABBVIE : Health Canada Approves AbbVie's RINVOQ® (upadacitinib) for the Treatment of Adult..
AQ
06/07ABBVIE : Results from IMBRUVICA (ibrutinib) RESONATE-2 Study Provide Up to Seven Years of ..
AQ
06/03ABBVIE : to Present Analysis Evaluating Continuous RINVOQ (upadacitinib) Treatment in Psor..
AQ
06/03ABBVIE : Phase 3 Maintenance Results Show Patients with Crohn's Disease Receiving Risankiz..
AQ
06/02ABBVIE : to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
PR
06/02ABBVIE : Phase 3 Maintenance Results Show Patients with Crohn's Disease Receiving Risankiz..
PR
05/27Ironwood Pharmaceuticals Announces Agreement with Teva Involving LINZESS (linaclotide) ..
AQ
05/26ABBVIE : to Present at Bernstein's 37th Annual Strategic Decisions Conference
PR
1  2  3  4  5  6  7  8  9  10Next
Upcoming event on ABBVIE INC.
10/14/21